# US 2013/0096163 A1 · Injectable dosage form of flupirtine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0096163 A1
- Document ID: US20130096163A1
- Status: Published application
- Kind: A1
- Application number: 13/704,277
- Filed: 2011-06-14
- Published: 2013-04-18
- Earliest claimed: 2010-06-14
- Assignees: Awd.Pharma GmbH & Co. KG
- Inventors: Christoph Martin Hoock; Asal Qadan; Bernd Terhaag; Rudy Thoma
- Web page: https://patentgrep.com/patent/US20130096163A1

## CPC

- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a flupirtine-containing lyophilisate, the use of this lyophilisate to produce a pharmaceutical composition to be parenterally applied, a procedure to produce a flupirtine-containing pharmaceutical composition to be parenterally applied, and a procedure to produce the flupirtine-containing lyophilisate as well as the flupirtine-containing pharmaceutical composition produced using the lyophilisate. For this purpose a lyophilisate is provided which contains the active ingredient flupirtine in the form of a physiologically tolerated salt, which has a solubility in water of at least 2.5 mg/ml, preferably at least 5 mg/ml, especially preferably at least 10 mg/ml, and contains one or more cyclodextrins or cyclodextrin derivatives, and which may be used to produce a pharmaceutical composition to be parenterally applied.

## Claims

### Claim 1

A lyophilisate, which contains a physiologically tolerated flupirtine sail with a solubility in water of at least 2.5 mg/ml as an active ingredient and furhter contains at least one cyclodextrin and/or cyclodextrin derivative.

### Claim 2 (depends on 1)

The lyophilisate according to claim 1, containing 50 mg to 250 mg flupirtine, relating to the free flupirtine base.

### Claim 3 (depends on 1)

The lyophilisate according to claim 1, wherein the flupirtine salt is selected from the group consisting of flupirtine mesilate, flupirtine besilate and flupirtine phosphate.

### Claim 4 (depends on 1)

The lyophilisate according to claim 1, wherein the flupirtine salt is flupirtine mesilate.

### Claim 5 (depends on 4)

The lyophilisate according to claim 4, further containing methanesulfonic acid in a quantity of 10 mg to 100 mg, preferably of 20 mg to 50 mg, especially preferably of 30 mg to 40 mg, relating to 100 mg of the free flupirtine base.

### Claim 6 (depends on 1)

The lyophilisate according to claim 1, wherein the cyclodextrin derivative is selected from the group consisting of hydroxypropyl-α-cyclodextrin, hydroxypropyl-β-cyclodextrin and hydroxypropyl-γ-cyclodextrin.

### Claim 7 (depends on 1)

The lyophilisate according to claim 1 wherein the cyclodextrin and/or cyclodextrin derivative is/are contained in a total quantity of 10 mg to 1000 mg, preferably of 30 mg to 300 mg, relating to 100 mg of the free flupirtine base.

### Claim 8 (depends on 9)

The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition to be parenterally applied is an injection solution and/or infusion solution.

### Claim 9 (depends on 1)

A pharmaceutical composition to be parenterally applied containing a lyophilisate according to claim 1.

### Claim 10 (depends on 9)

The pharmaceutical composition according to claim 9, obtained by dissolving the lyophilisate in an aqueous medium and/or in an organic solvent.

### Claim 11 (depends on 1)

A procedure to produce a lyophilisate according to claim 1, comprising the steps:
a) dissolving one or more cyclodextrins and/or cyclodextrin derivatives in an aqueous medium and/or an organic solvent,
b) introducing an acid which forms a physiologically tolerated salt with flupirtine base into the solution prepared in step a),
c) adding flupirtine base to the solution of step b),
d) heating and cooling the solution of step c),
e) if necessary, diluting the solution of step c),
f) if necessary, adjusting a pH value and a tonicity of the solution of step c),
g) freeze-drying the solution of step c).

### Claim 12 (depends on 11)

The procedure according to claim 11, wherein the aqueous medium used for dissolving the flupirtine base is healed in step d) to a temperature above room temperature and subsequently cooled to room temperature.

### Claim 13 (depends on 1)

A procedure to produce a flupirtine-containing pharmaceutical composition to be parenterally applied, wherein a lyophilisate according to claim 1 is dissolved in an aqueous medium and/or an organic solvent and a ready-to-use liquid pharmaceutical composition is obtained,

### Claim 14 (depends on 10)

The pharmaceutical composition according to claim 10, in the form of an injection solution to be applied intravenously and/or intramuscularly.

### Claim 15 (depends on 1)

A liquid flupirtine-containing pharmaceutical composition to be parenterally applied, produced by dissolving a lyophilisate according to claim 1.
